Sanofi vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends

SG&A Expense Trends: Sanofi vs Amphastar Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. Over the past decade, Sanofi and Amphastar Pharmaceuticals, Inc. have showcased distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Sanofi's SG&A expenses have consistently dwarfed those of Amphastar, averaging around $9.8 billion annually, compared to Amphastar's $58.8 million. This stark contrast highlights Sanofi's expansive operational scale and global reach.

Interestingly, while Sanofi's expenses have seen a modest increase of approximately 26% over the period, Amphastar's expenses have surged by nearly 99%, reflecting its aggressive growth strategy. The year 2023 marked a peak for both companies, with Sanofi reaching $10.8 billion and Amphastar hitting $80.4 million. These trends underscore the diverse strategies and market positions of these pharmaceutical giants.